Advertisement
Singapore markets open in 7 hours 46 minutes
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,031.73
    -39.90 (-0.79%)
     
  • Dow

    37,999.78
    -461.14 (-1.20%)
     
  • Nasdaq

    15,541.11
    -171.64 (-1.09%)
     
  • Bitcoin USD

    64,706.85
    -115.13 (-0.18%)
     
  • CMC Crypto 200

    1,391.58
    +9.01 (+0.65%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Gold

    2,340.00
    +1.60 (+0.07%)
     
  • Crude Oil

    82.48
    -0.33 (-0.40%)
     
  • 10-Yr Bond

    4.7000
    +0.0480 (+1.03%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Why Longeveron Stock Skyrockted 661.2% in November

Why Longeveron Stock Skyrockted 661.2% in November

Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.